Антибиотики и Химиотерапия (Mar 2022)
Dynamics of neurocognitive indicators against the background of neuroprotective therapy of vertebrobasilar insufficiency with cerebral venous discirculation symptoms
Abstract
The aim of the study was to assess the effect of Cytoflavin on the severity of neurocognitive parameters in patients with chronic cerebral ischemia, as well as vertebrobasilar insufficiency with symptoms of cerebral venous circulation. The study involved 60 patients who were divided into two groups. Cytoflavin was prescribed in the treatment group: once per day in the morning, slow intravenous drip of 10.0 ml per 200 ml of 0.9% sodium chloride solution, the duration of the infusion averaged 40–60 minutes for a course of 10 days with the transition to a tablet form — 2 tablets twice per day for 30 days against the background of standard basic therapy (acetylsalicylic acid and antihypertensive drugs). Patients in the comparison group received only basic therapy. The rating scales for headache (visual analogue scale) and asthenia (asthenic state scale) were used to assess the neurological status in addition to the standard clinical and labo ratory examination. It was revealed that the main clinical and neurological manifestations in patients with symptoms of cerebral venous discirculation are headaches (48 (80%) patients) and dizziness (53 (88.3%) patients). The incidence of dizziness increased with the progression of chronic cerebral ischemia, for example, at stage I dizziness occurred in 57% of cases, at stage II — in 78%, and at stage III — in 100%. When conducting a study of the headache severity dynamics on the VAS scale, a decrease in the intensity of headaches by 1.7 times (5.68±0.62 to 3.23±0.56 points, p[1]0.5) was noted in patients who received Cytoflavin, while only a slight decrease in the intensity of pain was noted in patients of the comparison group. In addition, the inclusion of the drug in the therapy regimens for patients with this pathology showed a significant decrease in the frequency of complaints, including specific «venous» complaints, the severity of cephalgic syndrome, as well as asthenic and autonomic disorders, which had a positive effect on the patients’ quality of life. The results obtained make it possible to recommend the inclusion of the drug in the therapy regimens for patients with symptoms of cerebral venous dysfunction.
Keywords
